New hope for kids: drug may shield against dangerous viruses after transplant

NCT ID NCT07488728

Recruiting now Disease control Sponsor: Beijing Children's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug letermovir can prevent serious viral infections in children with EBV-related blood disorders who receive a stem cell transplant. About 80 children will be enrolled, and researchers will monitor for infections and other transplant complications. The goal is to improve recovery and survival by reducing viral threats.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV-ASSOCIATED T/NK-CELL LYMPHOPROLIFERATIVE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

EBV-positive T-cell lymphoproliferative disorder of childhood Epstein-Barr virus-associated lymphoproliferative disorder secondary hemophagocytic lymphohistiocytosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBV-ASSOCIATED T/NK-CELL LYMPHOPROLIFERATIVE DISEASES LETERMOVIR REFRACTORY/RELAPSED EBV-RELATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS

Contacts and locations

Locations

Beijing Children's Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100032, China